Research Topics
| J G NuttSummaryAffiliation: Oregon Health and Science University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirementsJohn G Nutt
Neurology 66:1611-2; author reply 1611-2. 2006- Reduced performance in balance, walking and turning tasks is associated with increased neck tone in Parkinson's diseaseErika Franzén
Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
Exp Neurol 219:430-8. 2009..55, p<0.05). Our results suggest that neck tone plays a significant role in functional mobility and that abnormally high postural tone may be an important contributor to balance and mobility disorders in individuals with PD... - Parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonismParvoneh Poorkaj
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
BMC Neurol 5:4. 2005..A subset of familial PD exhibits anticipation, the cause of which is unknown. The aim of this study was to determine if anticipation was due to parkin mutation dosage... - Milestones in gait, balance, and fallingJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239, USA
Mov Disord 26:1166-74. 2011.... - Clinical practice. Diagnosis and initial management of Parkinson's diseaseJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland 97239, USA
N Engl J Med 353:1021-7. 2005 - Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?John G Nutt
Parkinson Center of Oregon, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
Mov Disord 22:1-9. 2007..Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized... - Freezing of gait: moving forward on a mysterious clinical phenomenonJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
Lancet Neurol 10:734-44. 2011..A better understanding of the phenomenon is needed to aid the development of effective therapeutic strategies... - Effects of methylphenidate on response to oral levodopa: a double-blind clinical trialJohn G Nutt
Department of Neurology, and Public Health and Preventative Medicine, Division of Biostatistics, Oregon Health and Science University, Portland, OR 97239, USA
Arch Neurol 64:319-23. 2007.... - Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and ParkinsonismJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, Oregon 97201, USA
Mov Disord 23:1860-6. 2008..However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects... - Pharmacokinetics and pharmacodynamics of levodopaJohn G Nutt
Department of Neurology, Oregon Health and Science University, Parkinson Disease Research, Education and Clinical Center, Portland VA, Oregon, USA
Mov Disord 23:S580-4. 2008..Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations... - Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective studyJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
Neurology 74:1191-7. 2010.... - The dopamine transporter: importance in Parkinson's diseaseJohn G Nutt
Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
Ann Neurol 55:766-73. 2004..These observations indicate that the residual DAT is functional in PD and is a potential target for symptomatic therapy of PD... - Interactions between deep brain stimulation and levodopa in Parkinson's diseaseJ G Nutt
Department of Neurology, Oregon Health Sciences University, Portland 97201, USA
Neurology 57:1835-42. 2001..To quantify the effects of deep brain stimulation (DBS) of globus pallidus interna (GPi) and subthalamic nucleus (STN) on motor fluctuations and dyskinesia in PD and to determine how the response to levodopa was modified by DBS... - Motor fluctuations and dyskinesia in Parkinson's diseaseJ G Nutt
Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland, OR 97201 3098, USA
Parkinsonism Relat Disord 8:101-8. 2001..A variety of clinical strategies may reduce the unpredictability of motor fluctuations and reduce their impact. Prevention of these complications remains an elusive goal... - Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PDJ G Nutt
Department of Neurology, School of Medicine, Oregon Health Sciences University, Portland 97201 3098, USA
Neurology 54:247-50. 2000..Apomorphine maintained the LDR to the extent that it kept the subjects "on" during the day. This observation suggests that the LDR can be a postsynaptic effect, independent of dopamine storage... - Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PDJ G Nutt
Oregon Health and Science University, Portland 97201 3098, USA
Neurology 60:69-73. 2003..To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter and access port in advanced PD... - Evolution of the response to levodopa during the first 4 years of therapyJohn G Nutt
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201 3098, USA
Ann Neurol 51:686-93. 2002..Improving the baseline or practical-off motor function to reduce the magnitude of the short-duration response may be a strategy to treat fluctuations... - DBS and diathermy interaction induces severe CNS damageJ G Nutt
Department of Neurology, Oregon Health Sciences University, Portland 97201 3098, USA
Neurology 56:1384-6. 2001..Pulse-modulated radiofrequency diathermy treatment to the maxilla produced permanent diencephalic and brainstem lesions and a vegetative state in a patient with PD with implanted subthalamic electrodes for deep brain stimulation... - Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot studyR Camicioli
Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
Clin Neuropharmacol 24:208-13. 2001..Methylphenidate increased the motor effects of L-Dopa with minimal effects on cognitive or affective functions, suggesting a physiologic role for the dopamine transporter in patients with PD with motor fluctuations... - Direction-specific postural instability in subjects with Parkinson's diseaseFay B Horak
Neurological Sciences Institute, Oregon Health and Science University, Portland, OR 97006-3499, USA
Exp Neurol 193:504-21. 2005..These results suggest that the basal ganglia, in addition to regulating muscle tone and energizing postural muscle activation, also are critical for adapting postural response patterns for specific biomechanical conditions... - A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PDR J St George
Department of Neurology, Oregon Health and Sciences University, 505 NW 185 Avenue, Beaverton, OR 97006, USA
Neurology 75:1292-9. 2010..This prompted us to conduct the first meta-regression of long-term studies of bilateral DBS in the subthalamic nucleus (STN) and globus pallidus interna (GPi)... - Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trialsSteven A Gunzler
Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, OR, USA
Clin Neuropharmacol 32:97-102. 2009..To explore foot-tapping rate as a reliable and a valid measure of motor function in Parkinson disease (PD)... - Response to levodopa treatment in dopa-responsive dystoniaJ G Nutt
Department of Neurology, OP 32, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201-3098, USA
Arch Neurol 58:905-10. 2001..The decline in motor function in DRD on withdrawal of long-term levodopa therapy resembles that in Parkinson disease, suggesting that a long-duration response, if it exists in DRD, is unrelated to dopamine storage... - Postural muscle responses to multidirectional translations in patients with Parkinson's diseaseDiana Dimitrova
Neurological Sciences Institute, Oregon Health and Science University, Beaverton, Oregon 97006-3499, USA
J Neurophysiol 91:489-501. 2004..These results are consistent with the hypothesis that PD results in an inability to shape the pattern and magnitude of postural muscle responses for changes in perturbation direction and in stance position... - Joubert syndrome surviving to adulthood associated with a progressive movement disorderSteven A Gunzler
Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, Oregon, USA
Mov Disord 22:262-5. 2007..This case demonstrates that a patient with Joubert syndrome may survive into adulthood and present as a chronic neurologic disorder with subacute extrapyramidal signs... - Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson diseaseMatthew A Brodsky
Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, OP 32, Portland, OR 97239
Arch Neurol 67:27-32. 2010..Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood... - Objective measurement of dyskinesia in Parkinson's disease using a force plateKathryn A Chung
Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
Mov Disord 25:602-8. 2010..Sensitivity to changes in LID was initially demonstrated but should be repeated. Thus, CoP recordings on a force plate can objectively quantify LID in PD and may be very useful in clinical trials or other investigations of dyskinesia... - Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated miceSteven A Gunzler
Parkinson s Disease Research, Education, and Clinical Center, Portland VA Medical Center, Portland, OR, USA
Neurosci Lett 428:64-7. 2007..Our results suggest that low doses of apomorphine can initially depress locomotion and subsequently stimulate locomotion, in a manner similar to what is seen in Parkinson's disease patients... - Preparation for compensatory forward stepping in Parkinson's diseaseLaurie A King
Department of Neurology, Oregon Health and Science University, Beaverton, OR, USA
Arch Phys Med Rehabil 91:1332-8. 2010..To characterize preparation for compensatory stepping in people with Parkinson's disease (PD) compared with healthy control subjects, and to determine whether levodopa medication improves preparation or the execution phases of the step... - Knee trembling during freezing of gait represents multiple anticipatory postural adjustmentsJesse V Jacobs
Department of Neurology, Oregon Health and Science University, Portland, OR 97239 3098, USA
Exp Neurol 215:334-41. 2009..These observations suggest that multiple APAs produce the knee trembling commonly associated with FoG and that FoG associated with a forward loss of balance is caused by an inability to couple a normal APA to the stepping motor pattern... - Effects of a central cholinesterase inhibitor on reducing falls in Parkinson diseaseKathryn A Chung
Department of Neurology, Oregon Health and Science University, Portland, OR, USA
Neurology 75:1263-9. 2010..To investigate if a central cholinesterase inhibitor will reduce falling frequency in subjects with Parkinson disease (PD) with advanced postural instability... - The instrumented timed up and go test: potential outcome measure for disease modifying therapies in Parkinson's diseaseCris Zampieri
Oregon Health and Science University, Department of Neurology, 505 NW 185th Avenue, Portland, OR 97006, USA
J Neurol Neurosurg Psychiatry 81:171-6. 2010..Thus, the iTUG test is sensitive to untreated PD and could potentially detect progression of PD and response to symptomatic and disease-modifying treatments... - Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot studyJau Shin Lou
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
Clin Neuropharmacol 32:305-10. 2009..Fatigue is a major nonmotor symptom in Parkinson disease(PD). It is associated with reduced activity and lower quality of life... - Short-term paroxetine treatment does not alter the motor response to levodopa in PDKathryn A Chung
Oregon Health and Science University, Portland, OR 97239 3098, USA
Neurology 64:1797-8. 2005..Paroxetine did not affect tapping scores or dyskinesia. Baseline walking speed (preinfusion) increased on paroxetine, often associated with an increased subjective perception of worsened balance... - Neuroimmunophilin ligands in the treatment of Parkinson's diseaseBruce G Gold
Center for Research on Occupational and Environmental Toxicology, Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, OR 97201 3098, USA
Curr Opin Pharmacol 2:82-6. 2002..To date, however, short-term treatments with two such compounds in a non-human primate model and in patients with Parkinson's disease have been disappointing... - OFF-off rebound dyskinesia in subthalamic nucleus deep brain stimulation of Parkinson's diseaseMatthew A Brodsky
Department of Neurology, Oregon Health and Science University, and Parkinson's Disease Research, Education and Clinical Care Center, Portland VA Medical Center, Portland, Oregon, USA
Mov Disord 21:1487-90. 2006..When the stimulators were turned back on, the dyskinesias soon resolved. This article is a first report of a unique pattern of rebound-type dyskinesia that occurred in the off medication state produced by stopping STN DBS... - Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's diseaseJohn G Nutt
Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, OP32, Portland, OR 97201-3098, USA
Exp Neurol 184:9-13. 2003 - Multiple balance tests improve the assessment of postural stability in subjects with Parkinson's diseaseJ V Jacobs
Neurological Sciences Institute, Oregon Health and Science University, Portland, OR, USA
J Neurol Neurosurg Psychiatry 77:322-6. 2006.... - Can stooped posture explain multidirectional postural instability in patients with Parkinson's disease?Jesse V Jacobs
Neurological Sciences Institute, Oregon Health and Science University, 505 NW 185th Avenue, Beaverton, Portland, OR 97006-3499, USA
Exp Brain Res 166:78-88. 2005..Upright and stooped control subjects never fell during the trials, whereas PD subjects fell in 16% of the trials. We conclude that stooped posture is a destabilizing posture, but it does not account for abnormal postural responses in PD... - Parkinson's diseaseAli Samii
Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA
Lancet 363:1783-93. 2004..This Seminar covers the basics, from terminology to aspects of diagnosis, treatment, and pathogenesis... - Analyzing 180 degrees turns using an inertial system reveals early signs of progression of Parkinson's diseaseArash Salarian
Department of Neurology, Oregon Health and Science University, Portland, OR, USA
Conf Proc IEEE Eng Med Biol Soc 2009:224-7. 2009..85). Turning duration also showed a significant Group *Time interaction (p<0.03) during the longitudinal study highlighting early signs of the progression of the disease... - An alternative clinical postural stability test for patients with Parkinson's diseaseJesse V Jacobs
Neurological Sciences Institute, Oregon Health and Science University, Beaverton, OR 97006-3499, USA
J Neurol 253:1404-13. 2006..The Push and Release Test correlated better with self-reported falls. Therefore, the Push and Release Test provided a more sensitive and consistent test of postural stability than the Pull Test... - Treatment of Parkinson's disease with trophic factorsAmie L Peterson
Parkinsons Disease Research, Educational and Clinical Center, Portland Veteran s Administration Medical Center, Portland, Oregon 97239, USA
Neurotherapeutics 5:270-80. 2008..Utility for such compounds in patients with Parkinson's disease and ongoing loss of dopaminergic neurons remains to be proven... - Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's diseasePhylinda L S Chan
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
J Pharmacokinet Pharmacodyn 32:307-31. 2005..Variability in levodopa pharmacokinetic parameters (particularly V1) may result in variability in plasma levodopa concentrations that could contribute to fluctuations in motor response... - Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's diseasePhylinda L S Chan
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
J Pharmacokinet Pharmacodyn 32:459-84. 2005.... - Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson diseaseAnthony E Lang
Toronto Western Hospital, University of Toronto, Ontario, Canada
Ann Neurol 59:459-66. 2006..This randomized controlled clinical trial was designed to confirm initial clinical benefits observed in a small, open-label trial using intraputamenal (Ipu) infusion of recombinant human GDNF (liatermin)... - Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulationPhylinda L S Chan
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
Pharm Res 24:791-802. 2007..To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial... - Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatmentsNicholas H G Holford
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
J Pharmacokinet Pharmacodyn 33:281-311. 2006..We have confirmed and quantitated the relative symptomatic benefits of the dopaminergic agents and provide model-based evidence for slowing of disease progression... - Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover studySteven A Gunzler
Movement Disorders Center, Neurological Institute, University Hospitals Case Medical Center and Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland, OH 44106, USA
Arch Neurol 65:193-8. 2008..To determine whether low concentrations of a dopamine agonist worsen parkinsonism, which would suggest that activation of presynaptic dopamine autoreceptors causes a super-off state... - Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)Sarah Furtado
Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada
Mov Disord 19:622-9. 2004..This review emphasizes the importance of testing for SCA2 in patients with parkinsonism and a family history of neurodegenerative disorders. Testing for SCA2 is also important in studies of inherited parkinsonism... - Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's diseasePhylinda L S Chan
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
J Pharmacokinet Pharmacodyn 31:243-68. 2004..The maximum levodopa induced response after the drug holiday is a result of lowered baseline tapping due to the loss of long-duration response and not due to a change in levodopa pharmacokinetics or pharmacodynamics... - Disease progression, drug action and Parkinson's disease: why time cannot be ignoredNick Holford
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand
Eur J Clin Pharmacol 64:207-16. 2008 - LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia agoCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Am J Hum Genet 79:752-8. 2006..Our data suggest two separate founding events for G2019S in these populations, beginning at a time that coincides with the Jewish Diasporas... - Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinicsDenise M Kay
Genomics Institute, Wadsworth Center, New York State Department of Health, Albany, 12201, USA
Mov Disord 21:519-23. 2006..Age at onset of mutation carriers ranged from 28 to 71 years. Mutation carriers were clinically indistinguishable from idiopathic PD. LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date... - GDNF in treatment of Parkinson's disease: response to editorialAnthony E Lang
Lancet Neurol 5:200-2. 2006 - Genetic association between alpha-synuclein and idiopathic Parkinson's diseaseDenise M Kay
New York State Department of Health, Division of Genetic Disorders, Wadsworth Center, Albany, New York 12208, USA
Am J Med Genet B Neuropsychiatr Genet 147:1222-30. 2008..1 for 261/261 to 59.4 +/- 11.5 for 257/257, displaying a trend of decreasing onset age with increasing allele size (P = 0.055). Genetic variation in SNCA and its regulatory regions play an important role in both familial and sporadic PD... - CSF multianalyte profile distinguishes Alzheimer and Parkinson diseasesJing Zhang
Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
Am J Clin Pathol 129:526-9. 2008..This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD... - Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's diseaseCyrus P Zabetian
Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
Ann Neurol 62:137-44. 2007..We sought to replicate these findings... - Exploring gene-environment interactions in Parkinson's diseaseColin C McCulloch
Applied Statistics Laboratory, General Electric Global Research Center, Niskayuna, NY, USA
Hum Genet 123:257-65. 2008..The novel findings of this study that warrant replication are the evidence for interaction of coffee with APOE, and of smoking with REP1 on PD risk... - Lack of evidence for an association between UCHL1 S18Y and Parkinson's diseaseCarolyn M Hutter
Department of Epidemiology, University of Washington, Seattle, WA, USA
Eur J Neurol 15:134-9. 2008..Our results suggest that UCHL1 S18Y is not a major susceptibility factor for PD in white populations although we cannot exclude the possibility that the S18Y variant exerts weak effects on risk, particularly in early-onset disease... - Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease riskKaren M Powers
Department of Environmental and Occupational Health Sciences, School of Public Health and Community Medicine, University of Washington, Seattle, Washington, USA
Mov Disord 23:88-95. 2008..13, 95% CI = 0.06-0.29). Whether this finding reflects true biologic protection needs to be investigated... - Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyAlexis Elbaz
INSERM, Unit 708, Paris, France
Lancet Neurol 5:917-23. 2006..INTERPRETATION: Our results do not lend support to the finding that the 13 SNPs reported in the original genome-wide association study are genetic susceptibility factors for Parkinson's disease...
Research Grants
- LEVODOPA PHARMACOKINETICS & PHARMACODYNAMICSJohn Nutt; Fiscal Year: 1991..These experiments will help define factors which modify the response to levodopa as well as the phenomenon which underlie the development of the fluctuating response...
- LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICSJohn Nutt; Fiscal Year: 1993..5. Follow a small cohort of parkinsonian patients from the initiation of levodopa therapy to study the emergence of the "short" and "long" duration responses to levodopa as well as dyskinesia and "negative" levodopa actions...
- Levodopa Pharmacokinetca and PharmacodynamicsJohn Nutt; Fiscal Year: 2003..abstract_text> ..
- LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICSJohn Nutt; Fiscal Year: 2007....
- LEVODOPA PHARMACOKINETICS AND PHARMACODYNAMICSJohn Nutt; Fiscal Year: 1999..The major thrust for this grant period is to determine the contribution of the LDR to the benefits of levodopa treatment and to suggest methods to selectively induce or augment the LDR. ..